<DOC>
	<DOCNO>NCT01704131</DOCNO>
	<brief_summary>Levosimendan drug use patient heart failure several advantage heart failure drug . A lot research do Levosimendan Adults , way body handle drug ( pharmacokinetics ) respond drug ( pharmacodynamics ) well establish . But , child information lack despite fact Levosimendan increasingly use child age . The investigator aim describe Levosimendan dose lead drug level child different age .</brief_summary>
	<brief_title>Levosimendan Pharmacokinetics Children</brief_title>
	<detailed_description>Rationale : Levosimendan , calcium-sensitizer , relatively new inotropic drug benefit conventional inotropes increase myocardial oxygen demand lead arrhythmia . Levosimendan relatively unique pharmacokinetic profile , 24 hour infusion clinical effect remain several day . This achieve continue haemodynamic effect active metabolite , half life approximately 80 hour compare 1 hour Levosimendan . Levosimendan extensively study adult use ischemic heart disease , acute heart failure , chronic heart failure , follow cardiac surgery , septic shock . Due inotropic property strong pulmonary vasodilatory effect , Levosimendan could also useful perioperative therapy child congenital heart disease , low cardiac output , pulmonary artery hypertension . Although experience levosimendan child still scarce literature , initial report promise Levosimendan use often ( rescue ) therapy child heart failure . However , current dosing regimen child base adult pharmacokinetic evidence . One pediatric report suggest pharmacokinetic profile single load dose Levosimendan probably similar child older 6 month compare adult . The pharmacokinetic profile 24-hour infusion Levosimendan yet study child . It important study pharmacokinetics useful drug different age group diversity population due age , volume distribution , ontogeny metabolize enzyme , influence disease state pharmacokinetics pharmacodynamics . Objective : To describe pharmacokinetic profile 24 hour infusion levosimendan active metabolite child acute chronic heart failure . Study design : Observational study Levosimendan level child treat Levosimendan heart failure . Study population : Children ( &lt; 16 year ) admit pediatric intensive care unit , acute chronic heart failure . Intervention ( applicable ) : intervention Main study parameters/endpoints : The primary endpoint study describe pharmacokinetic profile determine plasma level levosimendan metabolites 12 day follow 24-hour infusion child heart failure different age group . Secondary endpoint clinically measure hemodynamic variable ( heart rate , bloodpressure , lactate , troponin , pro-BNP , venous saturation ) echocardiographic variable ( ejection fraction , shorten fraction , tissue Doppler ) patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>All child admit Pediatric Intensive Care Unit Acute Heart Failure receive Levosimendan part treatment . informed consent sample line</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Levosimendan</keyword>
	<keyword>Children</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>